myCMEOptimizing Treatment Plans and Goals of Care for Metastatic Breast Cancer with CDK4/6 Inhibitors

This educational program aims to improve the knowledge and comprehension of the clinical trial and real-world evidence for the CDK4/6i class among HCPs. A greater percentage of patients with HR+/HER2 metastatic breast cancer (mBC) will have access to this therapeutic option by filling care gaps linked to CDK4/6i usage. The course will largely center on three (3) core learning areas: best practices in CDK4/6i therapy management, the significance of real-world evidence (RWE) in treatment decision-making, and CDK4/6i in mBC: indications, clinical data, and RWE.